REXULTI® (brexpiprazole) Patient Information Website

Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies

REXULTI® (brexpiprazole) Patient Information Website

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease

REXULTI® (brexpiprazole), MDD

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® ( brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

PM360 2021 Trailblazer Awards Co-Promote or Partnership Initiative Gold Winner Otsuka, Lundbeck, and The Bloc

Table 1 from Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.

Rexulti Full Prescribing Information, Dosage & Side Effects

Huntington's Symptoms Eased by Rexulti, Case Report Shows

Decision on Brexpiprazole for Alzheimer's Agitation Due in May